Newsroom

For all company announcements, please refer to SGX company disclosures page.

10

November 2020

Tuesday

iX Biopharma is pleased to announce that it has received positive feedback from the European Medicines Agency (EMA) in its scientific advice to the Company regarding its Phase 3 clinical development programme for Wafermine, its sublingual ketamine wafer, for registration in Europe.

More information can be found in the attached press release.

28

October 2020

Wednesday

The management of iX Biopharma presented at a guest webinar hosted by Phillip Securities.

The presentation slides can be viewed here.

20

October 2020

Tuesday

iX Biopharma is pleased to announce the approval and registration of its male erectile dysfunction drug, Silcap, in Singapore

More information can be found in the attached press release.

16

October 2020

Friday

The Board of Directors of iX Biopharma Ltd. is pleased to announce that at the Annual General Meeting (AGM) of the Company held by electronic means today, all resolutions set out in the Notice of AGM dated 1 October 2020 were duly passed by way of a poll vote.

The results of AGM can be found at this link.

A Corporate Update was also presented at the end of the AGM. The presentation slides and video recording are available here:

Corporate Update presentation slides

Link to video recording: https://youtu.be/hYNDn4Tb3uc

14

October 2020

Wednesday

iX Biopharma wishes to address key questions received from the Shareholders ahead of the upcoming annual general meeting to be held on 16 October 2020.

The questions and answers can be viewed at this link.

01

October 2020

Thursday

iX Biopharma Ltd has published its Annual Report for FY2020 which can be found here.

iX Biopharma Ltd has released its letter to shareholders, and other related documents, on alternative arrangements for the upcoming Annual General Meeting of the company to held on 16 October 2020.

AGM Letter to Shareholders

Notice of AGM

AGM Proxy Form

Registration URL Link for Shareholder attendance of the AGM: https://complete-corp.com.sg/ix-biopharma-agm/

Email address for submission of AGM Proxy Form: ixbiopharma-agm@complete-corp.com.sg

Shareholders who wish to submit questions may do so via the registration website at https://complete-corp.com.sg/ix-biopharma-agm/ or by email to ixbiopharma-agm@complete-corp.com.sg

28

September 2020

Monday

iX Biopharma Ltd is pleased to announce that it has secured TGA GMP license for its testing laboratory.

More information can be found in the attached press release.

21

September 2020

Monday

iX Biopharma Ltd is pleased to announce that it has been granted a patent in Israel for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

09

September 2020

Wednesday

iX Biopharma Ltd has announced the allotment and issue of 44,491,299 Subscription Shares on 8 September 2020.

The announcement can be found here.

07

September 2020

Monday

The minutes for iX Biopharma’s Extraordinary General Meeting held on Friday, 4th September can be found here.

04

September 2020

Friday

iX Biopharma Ltd has reported results of the extraordinary general meeting  held on Friday, 4 September 2020 to seek shareholders' approval for the proposed allotment and issue of 44,491,299 new ordinary shares.

The results can be found here.

28

August 2020

Friday

iX Biopharma Ltd has reported results for the second half and full financial year ended 30 June 2020.

The fourth quarter financial statements for the period can be found here.

 

28

August 2020

Friday

iX Biopharma Ltd has issued its response to address key questions received from the Shareholders ahead of the upcoming extraordinary general meeting to be held on 4 September 2020 and has provided an update of the financial effects of the proposed placement of 44,491,299 new ordinary shares.

More information on the Q&A can be found in the attached press release. The financial effects of the proposed placement can be viewed at this link.

27

August 2020

Thursday

A change in particulars of subscriber has been announced for the proposed placement of 44,491,299 new ordinary shares in the capital of iX Biopharma Ltd.

Please refer to the attachment in relation to the Change in Particulars of Subscriber.

11

August 2020

Tuesday

The Directors of iX Biopharma Ltd are convening an extraordrinary general meeting of the Company to be held by way of electronic means on 4 September 2020 at 10 a.m. to seek Shareholders' approval for the proposed allotment and issue of 44,491,299 new ordinary shares.

Letter to Shareholders

Placement Circular

EGM Proxy Form

Registration URL Link for Shareholder attendance of the EGM: https://complete-corp.com.sg/ix-biopharma-egm/

Email address for submission of EGM Proxy Form: ixbiopharma-egm@complete-corp.com.sg

Shareholders who wish to submit questions may do so via the registration website at https://complete-corp.com.sg/ix-biopharma-egm/ or by email to ixbiopharma-egm@complete-corp.com.sg

 

04

August 2020

Tuesday

iX Biopharma Ltd is pleased to announce the allowance of WaferiX™ Patent by United States Patent and Trademark Office, enhancing Wafermine™ Intellectual Property Protection.

More information can be found in the attached press release.

 

29

July 2020

Wednesday

iX Biopharma Ltd has announced a proposed placement of 44,491,299 new ordinary shares.

More information can be found in the attached press release.

30

June 2020

Tuesday

iX Biopharma Ltd is pleased to announce robust uptake of Xativa™ following its launch in Australia at the end of April 2020. Its initial production runs of approximately 1700 boxes of Xativa™, a sublingual medicinal cannabidiol (“CBD”) wafer, have been fully sold.

More information can be found in the attached press release.

09

June 2020

Tuesday

iX Biopharma Ltd is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application entitled “Fast Dissolving Solid Dosage Form” (U.S. Patent Application No. 13/504,309).

More information can be found in the attached press release.

26

May 2020

Tuesday

iX Biopharma Ltd. is pleased to announce that it has commenced supply of Wafesil® and Silcap®, which are medicines for the treatment of male erectile dysfunction, through telemedicine in Australia.

More information can be found in the attached press release.

11

May 2020

Monday

Read our update on impact of COVID-19 on business operations from iX Biopharma Chairman & CEO here.

06

May 2020

Wednesday

iX Biopharma Group’s Xativa product, the world’s first medicinal cannabis sublingual wafer, has been featured on Channel 9 News Brisbane.


Watch the news feature here

Read more

04

May 2020

Monday

Entity has seen exceptional demand for its LumeniX and RestoriX nutraceutical products less than three weeks into the opening of Entity flagship stores on JD Worldwide and Tmall Global.

More information can be found in the attached press release.

29

April 2020

Wednesday

iX Biopharma inks agreement with Cannatrek to supply Xativa™, the world’s first freeze-dried sublingual medicinal cannabis wafer, to the Australian market.

More information can be found in the attached press release.

27

April 2020

Monday

iX Biopharma Ltd is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. for the licensing, supply and distribution of Wafesil™, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

More information can be found in the attached press release.

13

April 2020

Monday

iX Biopharma Ltd is pleased to announce the opening of Entity’s new flagship store on Tmall Global (“Tmall”), Alibaba Group’s cross-border B2C e-commerce platform.

More information can be found in the attached press release.

 

06

April 2020

Monday

iX Biopharma Ltd is pleased to announce the opening of the Entity flagship store on JD Worldwide, JD.com’s cross-border e-commerce platform. JD Worldwide provides a platform for Chinese consumers to purchase authentic imported products and enables international suppliers to sell directly to Chinese consumers without requiring an established presence in China.

More information can be found in the attached press release.

 

11

February 2020

Tuesday

iX Biopharma Ltd. has reported results for the second quarter and/or half yearly results as of 31 December 2019.

The second quarter financial statements for the period can be found here.

30

January 2020

Thursday

iX Biopharma Ltd has published its presentation for Phillip securities Jan 2020.

The presentation can be found here.

10

December 2019

Tuesday

iX Biopharma Ltd is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublingual ketamine wafer for the treatment of acute moderate to severe pain.

More information can be found in the attached press release.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com